Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Thrombotic risk with thrombopoietin receptor agonists in immune thrombocytopenia: Real-world evidence from a multicenter Japanese study.

View Full Paper
Ask AI
Bookmark
Share

Authors

HHHiroto HoriguchiTKTakeshi KondoYKYasutaka Kakinoki

Discussion

Loading...

Member takes

Overview

Observational analysis revealed thrombotic events in 4.5% of patients treated with TPO-RAs, indicating risks linked to antiphospholipid antibodies.

Key Points

  • Thrombotic events occurred in 31 of 687 patients across 20 centers, with a notable portion in those treated with TPO-RAs.
  • Multivariate analysis identified antiphospholipid antibody positivity and prior thrombosis as independent risk factors for thrombosis.
  • Patients with a thrombotic history had a significantly higher cumulative incidence of thrombosis when treated with TPO-RAs.
  • Careful monitoring and risk stratification are critical when prescribing TPO-RAs to high-risk immune thrombocytopenia patients.

Cite This Study

Horiguchi et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d912https://doi.org/10.1182/blood-2025-1259
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Beyond Platelet Counts: Assessing Safety of Post-Splenectomy TPO-RA Use in ITP2025
  2. 2Efficacy and Thrombotic Risk of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia Secondary to Systemic Lupus and Antiphospholipid Syndrome: French Experience With 80 Patients2025
  3. 3Bridging the gaps between randomized controlled trials and real-world use of thrombopoietin receptor agonists for adult primary immune thrombocytopenia: a systematic review and meta-analysis2025 · 1 citations
  4. 4Relationship between thromboembolic events and thrombopoietin receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report.2025
  5. 5Impact of Primary Chronic Immune Thrombocytopenia and Thrombopoietin Receptor Agonists Treatment Instructions on Daily Living: Results of a Multinational Cross-Sectional Survey2025